• Defence Therapeutics named Ryan Simms as chief operating officer, adding oversight of its radiopharmaceutical programs.
• Simms previously led chemistry, radiochemistry, clinical manufacturing, and external partnerships at Fusion Pharmaceuticals across multiple clinical-stage programs.
• He also held leadership roles at Abdera Therapeutics and CPDC, focusing on CMC strategy, manufacturing, isotope supply, radiochemistry, and operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Defence Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608170315NEWSFILECNPR____20260817_309710_1) on August 17, 2026, and is solely responsible for the information contained therein.